本文選題：胰高血糖素　切入點(diǎn)：學(xué)術(shù)合作　出處：《中國(guó)醫(yī)院藥學(xué)雜志》2016年05期 　論文類(lèi)型：期刊論文

【摘要】：正自2005年國(guó)際上第一個(gè)腸促胰素類(lèi)藥的上市以來(lái),此類(lèi)藥物的研究和臨床應(yīng)用有了飛速的發(fā)展。目前在我國(guó)己經(jīng)上市的2種胰高血糖素樣肽1(GLP-1)受體激動(dòng)劑和5種二肽基肽酶IV(DPP-4)抑制劑,為了促進(jìn)腸促胰素類(lèi)藥物在臨床應(yīng)用方面的經(jīng)驗(yàn)交流,加強(qiáng)學(xué)術(shù)合作,《中國(guó)醫(yī)院藥學(xué)雜志》與阿斯利康(中國(guó))聯(lián)合向全國(guó)藥學(xué)
[Abstract]:Since 2005, when the first enteropancreatins were launched in the world, The research and clinical application of these drugs have developed rapidly. Two glucagon-like peptide (GLP-1) receptor agonists and five dipeptidyl peptidase (IVP) -DPP-4) inhibitors have been listed in China. In order to promote the exchange of experience in clinical application of enteropancreatins and strengthen academic cooperation, the Chinese Journal of Hospital Pharmacy and AstraZeneca (China) have joined hands with AstraZeneca (China) in the field of pharmacology throughout the country.
【作者單位】： 腸促胰素類(lèi)藥物研究與評(píng)價(jià)征文與優(yōu)秀病例分析征集組委會(huì);
【分類(lèi)號(hào)】：+
，

本文編號(hào)：1608509